Pediatric Psychopharmacology National Institute of Mental Health.

Slides:



Advertisements
Similar presentations
Other Mental Health Issues that Impact Learning
Advertisements

Development of School Mental Health Programs Sheldon D. Glass, M.Ed, M.D. Assistant Professor of Psychiatry, Johns Hopkins School of Medicine Member, National.
Pharmacologic Treatments. 2 Cognitive Behavioural Therapy (CBT) Psychosocial Interventions.
Depression in Children and Adolescents Graham J. Emslie, M.D. UT Southwestern Medical Center at Dallas and Children’s Medical Center.
Current and Future Challenges in Designing Behavioral Interventions: From Randomized Trials to Community Implementation Current and Future Challenges in.
1 Timing and Duration of Relapse Prevention Trials in Psychiatric New Drug Development David Michelson, M.D. Executive Director, Neuroscience Medical Research.
Linking Actions for Unmet Needs in Children’s Health
Visit our websites: PhD Study: Evaluation of the Efficacy of the Incredible.
Progress Towards the Triple-Aim Behavioral Health and Care Coordination Integration Michael W. Yogman, MD, FAAP Susan Betjemann, LICSW Christopher Ortengren.
North Central Action Network Projects  Ohio’s Shared Agenda Support ~ Hosted a Forum in Wooster, Ohio at the local High School “Addressing Barriers to.
Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.
EVIDENCE-BASED MENTAL HEALTH PRACTICES Anthony F. Lehman, M.D., M.S.P.H. Professor and Chair Department of Psychiatry University of Maryland.
Behavioral Health Screening & Referral in Pediatric Clinics
Behavioral Health & Wellness Program Department of Psychiatry University of Colorado Denver
The Evidence Base for Psychosocial and Psychopharmacological Interventions for Children with Attention-Deficit/Hyperactivity Disorder, Major Depressive.
Perinatal Mental Health HIT IMPROVE (Improving Mental Health Perinatally through Research and Education) Implementing evidence; generating evidence.
Perspective in pediatric nursing
From Blue to You Depression in Children and Adolescents.
1 Informative Studies of New Therapeutic Agents in Major Depression, GAD & Panic W Z Potter, M.D., PhD. Merck Research Laboratories.
CHIPRA Quality Demonstration Grant and Pennsylvania’s Early Intervention Strategies David Kelley MD, MPH Chief Medical Officer Office of Medical Assistance.
John M. Diamond, MD Professor and Head, Division of Child and Adolescent Psychiatry Brody School of Medicine at East Carolina University.
Adolescent Depression Mary Ann Hudson, RN College of Nursing The Ohio State University.
Depression in Adolescents and Young Adults: current best practice David Hartman Psychiatrist Child, Adolescent and Young Adult Service Institute of Mental.
Ohio Justice Alliance for Community Corrections October 13, 2011.
ADHD& CO-morbidities Dr. Fatima Al-Haidar Professor & Consultant Child and Adolescent Psychiatrist.
Treatment for Adolescents With Depression Study (TADS)
Mission: Protect the Vulnerable, Promote Strong and Economically Self- Sufficient Families, and Advance Personal and Family Recovery and Resiliency. Charlie.
Sleep in the Pediatric Practice M. Mohammadi MD Professor of Pediatrics & Neurology Children’s Medical Center Hospital October 2005.
June 11, IOM, Reducing Suicide, 2002 Statement of Task w Assess the science base w Evaluate the status of prevention w Consider strategies for studying.
By: Christina Taimalelagi. Introduction  Bipolar disorder is a serious brain illness. National institute of mental health. (11, October 12).
An Overview of Mental Health and Children Abram Rosenblatt, Ph.D. University of California, San Francisco.
Study Design for a Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit.
BIPOLAR DISORDER The management of bipolar disorder in adults, children and adolescents, in primary and secondary care National Institute for Health and.
From Blue to You Depression in Children and Adolescents.
Behavioral Health Consultation Services - Pediatric a program to Support Behavioral Healthcare Practice in Pediatric Primary Care SmartCare.
Depression Care Management Lessons from Project IMPACT _____________________________________________________ Jürgen Unützer, MD, MPH Professor and Vice.
Treatment Resistant Pediatric BD Elham Shirazi M.D. Board of General Psychiatry Board of Child & Adolescent Psychiatry.
Brandon A. Gaudiano, Ph.D. Warren Alpert Medical School of Brown University Butler Hospital Providence, Rhode Island.
Sertraline Use in Pediatric Population: A Risk Benefit Discussion Steven J. Romano, MD September 13, 2004 Steven J. Romano, MD September 13, 2004 Joint.
Plenary III: There is No Health Without Mental Health.
Long-term Efficacy Data for Psychiatric Drugs Rationale for Long-Term Treatment Earl Giller, MD, PhD Pfizer Global Research & Development Long-Term Efficacy.
M eaningful Quality Measures for Children with Behavioral Health Conditions Discussion with the NYS Conference of Local Mental Health Hygiene Directors.
Access to drugs, Reducing bottlenecks Matt Cooper Business Development & Marketing Director NIHR Clinical Research Network
Effectiveness of Cognitive Behavioral Therapy and Selective Serotonin Reuptake Inhibitors in Adolescents with Depression Megan Boose, PA-S Evidence Based.
MENTAL AND BEHAVIORAL DISORDERS PSYCHOLOGY DAY 19, 20, 21, 22, 23, & 24.
Long-Term Efficacy Data for Psychiatric Drugs Thomas Laughren, M.D. Director, Division of Psychiatry Products (HFD-130) PDAC Meeting (Oct 25, 2005)
1 International Society for CNS Clinical Trials and Methodology FDA Advisory Committee Meeting Proposed Requirement for Long-Term Data to Support Initial.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Child & Adolescent Bipolar Foundation Lithium testing in children: a Public Health Necessity June 11, 2002 Martha Hellander, J.D., Executive Director.
Practice Key Driver Diagram. Chapter Quality Network ADHD Project Jeff Epstein PhD CQN ADHD National Expert/CQN Data Analyst The mehealth Portal and CQN.
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
Introduction to DSM. Diagnostic and Statistical Manual of Mental Disorders  Published by the American Psychiatric Association  Provides standard diagnostic.
Integrating Tobacco Prevention Strategies into Behavioral Parent Training for Adolescents with ADHD Rosalie Corona, Ph.D. Associate Professor of Psychology.
Long-term Efficacy for Psychiatric Drugs Frederick K. Goodwin, MD George Washington University Medical Center Frederick K. Goodwin, MD George Washington.
An Innovative Mental Health Center. Reasons for HOPE: Advances in Mental Health Care Presented by Paul E. Keck, Jr., M.D. President and Chief Executive.
Julia London Educational & Developmental Psychologist and Clinical Psychologist at RPCS.
Behavioral Health INTEGRATION Recent literature, conceptual frameworks & options for next steps October 16, 2013 Mark Gibson Director Center for Evidence-based.
Long-term Effects of Mental Health Interventions in Children Benedetto Vitiello, M.D. Roma, 11 May 2012.
Ready to Use, Basic Psychopharmacology Didactic Curriculum 2014 Behavioral Sciences in Family Medicine Conference Yvonne Murphy, MD Associate Program Director.
Disorders of Childhood & Adolescence Chapter 17 1.
Prof Fareed Aslam Minhas
Algorithms for Mental Health Conditions
Seattle & King County School Based Health Centers
Depression: How to diagnose and how to start treatment
24/04/2012 NICE guidance and best practice in psychological care for “bipolar disorder” Dr Graeme Reid, Consultant Clinical Psychologist, Step 5, Central.
Destigmatizing Mental Illness
So far, we have covered: Adolescent Development
Scientific Update.
The Challenges of Bipolar Disorders
Trial Funding and Engagement: The NIH Sponsored CTSA Program
Presentation transcript:

Pediatric Psychopharmacology National Institute of Mental Health

Child and Adolescent Treatment and Preventive Intervention Research Branch Mission: To promote, conduct, and coordinate federally funded research on the effects of treatment and prevention of mental illness in children and adolescents

Primary Research Questions 1. What is the efficacy/effectiveness and safety of the most commonly used treatment and preventive interventions? 2. How current interventions can be improved? 3. How novel interventions can be developed?

Primary Research Questions 4. What is the long-term impact of treatments? 5. How to address treatment non- response? 6. Which interventions for which patients? 7. What is the impact of comorbidity? 8. How do interventions work?

Child and Adolescent Treatment and Preventive Intervention Research Branch

Research funding in 1999 (millions): Prevention$ 18.2 Psychosocial Tx$ 7.1 Psychopharm.$ 5.9 Combined Tx$ 9.3

Child and Adolescent Treatment and Preventive Intervention Research Branch Major areas of funding by disorder (1999, in millions) Depression$ 8.0 Anxiety$ 2.6 ADHD$ 2.5 Autism$ 2.2

l R esearch l U nits l P ediatric l P sychopharmacology Network

Research Units on Pediatric Psychopharmacology l Network of research units devoted to multi-site clinical trials in children l Units are at academic research settings l Main focus is on efficacy and safety of psychotropic medications that are commonly used in children without adequate data l Established in through competitive contracts

Research Units on Pediatric Psychopharmacology Columbia UniversityL. Greenhill, M.D. Johns Hopkins UniversityM. Riddle, M.D. Pittsburgh UniversityB. Birmaher, M.D. Yale UniversityF. Volkmar, M.D. UCLAJ. McCracken, M.D. Indiana UniversityC. McDougle, M.D. Ohio State UniversityM. Aman, Ph.D.

Research Units on Pediatric Psychopharmacology l Each RUPP has experts in child psychiatry, psychopharmacology, pediatrics, clinical trial design and methods l Data management center l Network statistician l The network as a resource available to potential sponsors of clinical trials in children (e.g., NIH, industry, private foundations)

Research Units on Pediatric Psychopharmacology NIMH supports: l Basic infrastructure for the units l Data management center l Specific protocols in areas that are: 4 Of public health importance 4 Not funded, or unlikely to be funded through grant mechanisms 4 Not sponsored by industry

Research Units on Pediatric Psychopharmacology Some Multisite Protocols: l SSRI for Children with Anxiety Disorders l Risperidone for Children with Autism and Behavioral Disturbances l SSRI for Depressed Children with Bipolar Disorder l Sequential Treatments for Children with Comorbid ADHD and Anxiety Disorders

TADSTADS Treatment for Adolescents with Depression Study

Primary Aims To compare the effectiveness of FLX, CBT, COMB, and PBO for reducing MDD symptoms and patient disability acutely. To compare the effectiveness of the three active treatments (FLX, CBT, and COMB) during long-term treatment. To compare the speed of response of FLX, CBT and COMB.

TADS N=432 Age: years Dx: major depression Design: parallel-group Tx: Med, CBT, CBT+Med, Placebo Sites: 10

Stages of Treatment Model Stage I: Acute treatment for 12 weeks Stage II: Consolidation for 6 weeks Stage III: Maintenance for 18 weeks Stage IV: One year open follow-up

Recently Funded Grants Relapse prevention in youths with depression Treatment of SSRI-resistant depression in adolescents Mood stabilizers for youths with bipolar Efficacy and safety of methylphenidate in preschoolers with ADHD

Preschool ADHD Treatment Study Age 3-5 yrs (N=198) vs. Age 6-8 yrs (N=66) Screening/evaluation8 weeks Open titration3 weeks Placebo-controlled trial12 weeks Open maintenance 10 months Blinded discontinuation6 weeks

Some areas in need of expansion Schizophrenia and other psychoses Bipolar Depression in prepubertal children Autism Comorbid conditions